BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

Grants

Funding Acknowledgements

This work was supported by research funding from the Leukaemia Foundation of Australia (S.J.H.), the Cancer Therapeutics CRC (S.J.H.), a Kids Cancer project grant (S.J.V.), a Rubicon Postdoctoral Fellowship (S.J.V.; NWO 019.161LW.017), the Eva and Les Erdi/Snowdome Foundation (J.S.,SNOW04), the Cancer Council Victoria (APP1081422), the National Health and Medical Research Council of Australia (NHMRC, APP1077867), the Victorian Cancer Agency, SFB project grants F4704 (P.V.) and F4710 (J.Z.) of the Austrian Science Fund (FWF), a Marie-Curie Fellowship of the European Union (S.D.) and a Starting Grant (ERC 336860) of the European Research Council (J.Z.). We thank members of the Johnstone lab, Garth Cameron and Dale Godfrey (Peter Doherty Institute, Australia) for helpful discussions, Prof. Mark Dawson and Dr. Chun Fong for reagents and advice, Dr. Anoop Kavirayani (VBCF, Austria) for histology support, Prof. Maher Gandhi (UoQ Diamantina Institute, Australia) for L540 cells, Prof. Huey-Kang Sytwu (National Defense Medical Center, Taipei) for murine Pd-l1 cDNA, and Dr. Ross Dickins (Monash University, Australia) for Myc shRNAs. The Dana-Farber Cancer Institute has licensed intellectual property from the Bradner Laboratory concerning BET bromodomain inhibitors to Tensha Therapeutics, now owned by Roche Pharmaceuticals. The Johnstone Laboratory receives funding to conduct studies associated with JQ1.